European Journal of Clinical Pharmacology

, Volume 73, Issue 2, pp 241–248 | Cite as

Antiepileptic drug use in Italian children over a decade

  • Daria Putignano
  • Antonio Clavenna
  • Rita Campi
  • Angela Bortolotti
  • Ida Fortino
  • Luca Merlino
  • Aglaia Vignoli
  • Maria Paola Canevini
  • Maurizio Bonati
Pharmacoepidemiology and Prescription



The aim of the study was to evaluate prescription profiles of antiepileptic drugs (AEDs) and to assess hospitalizations and specialist visits in pediatric patients with epilepsy.


The data sources were administrative health databases of Italy’s Lombardy Region, which collect prescriptions for drugs, diagnostic tests, specialist visits, and hospital discharge forms. All patients aged 0–16 years with at least seven AED (group N03A of the International Anatomical Therapeutic Chemical Classification) prescriptions over two consecutive years between 2003 and 2010 were identified and classified as prevalent or incident cases (no prescriptions in two previous years). The first prescription to incident cases was analyzed. For each incident case, drug prescriptions, specialist visits, diagnostic tests, and hospitalizations in the 24 months following the first (index) prescription were monitored.


A total of 6527 incident cases (5.4/10,000 person-years, 95% CI 5.4–5.5) were identified. Valproic acid and carbamazepine were the most prescribed drugs (65.9 and 15.0%, respectively). The use of newer AEDs increased over time. In the 24-month observation period, 74% of incident cases continued the treatment with the index AED. The percentage of cases who changed therapy was higher in preschoolers (34%) and decreased with age. In all, 21% of incident cases were hospitalized for epilepsy and 86% had a specialist visit in the 24 months after the first AED prescription.


In conclusion, older AEDs, particularly valproic acid, remained the first therapeutic approach to pediatric epilepsy in Italy. For three quarters of cases, the initial AED treatment was likely effective and well tolerated.


Drug utilization Prescription Anticonvulsants Epilepsy Pharmacoepidemiology 

Supplementary material

228_2016_2168_MOESM1_ESM.docx (13 kb)
Supplementary Table 1(DOCX 12 kb)
228_2016_2168_Fig3_ESM.gif (61 kb)
Supplementary Figure s1

(GIF 61 kb)

228_2016_2168_MOESM2_ESM.tif (47 kb)
High Resolution (TIFF 47 kb)


  1. 1.
    Perrin JM, Anderson LE, Van CJ (2014) The rise in chronic conditions among infants, children, and youth can be met with continued health system innovations. Health Aff (Millwood) 33(12):2099–2105. doi:10.1377/hlthaff.2014.0832 CrossRefGoogle Scholar
  2. 2.
    Forsgren L (2004) Incidence and prevalence. In: Wallace SJ, Farrell K (eds) Epilepsy in children, 2nd edn. Arnold, London, pp. 21–25CrossRefGoogle Scholar
  3. 3.
    Guerrini R (2006) Epilepsy in children. Lancet 367(9509):499–524. doi:10.1016/S0140-6736(06)68182-8 CrossRefPubMedGoogle Scholar
  4. 4.
    Passi GR (2014) Newer antiepileptic drugs: evidence based use. Indian J Pediatr 81(10):1042–1051. doi:10.1007/s12098-014-1494-4 CrossRefPubMedGoogle Scholar
  5. 5.
    Ackers R, Murray ML, Besag FM, Wong IC (2007) Prioritizing children’s medicines for research: a pharmaco-epidemiological study of antiepileptic drugs. Br J Clin Pharmacol 63(6):689–697. doi:10.1111/j.1365-2125.2006.02842.x CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT (2008) Antiepileptic drug utilization in children from 1997 to 2005—a study from the Netherlands. Eur J Clin Pharmacol 64(10):1013–1020. doi:10.1007/s00228-008-0480-z CrossRefPubMedGoogle Scholar
  7. 7.
    Giussani G, Cricelli C, Mazzoleni F et al (2014) Prevalence and incidence of epilepsy in Italy based on a nationwide database. Neuroepidemiology 43(3–4):228–232. doi:10.1159/000368801 CrossRefPubMedGoogle Scholar
  8. 8.
    Casetta I, Pugliatti M, Faggioli R, Cesnik E, Simioni V, Bencivelli D, De Carlo L, Granieri E (2012) Incidence of childhood and adolescence epilepsy: a community-based prospective study in the province of Ferrara and in Copparo, Italy, 1996-2005. Eur J Neurol 19(2):312–316. doi:10.1111/j.1468-1331.2011.03506.x CrossRefPubMedGoogle Scholar
  9. 9.
    Clavenna A, Cartabia M, Sequi M, Costantino MA, Bortolotti A, Fortino I, Merlino L, Bonati M (2013) Burden of psychiatric disorders in the pediatric population. Eur Neuropsychopharmacol 23(2):98–106. doi:10.1016/j.euroneuro.2012.04.008 CrossRefPubMedGoogle Scholar
  10. 10.
    National Institute for Clinical Excellence (2012) Epilepsies: diagnosis and management. Clinical guideline [CG137]. Accessed 08 Sept 2016
  11. 11.
    Jette N, Beghi E, Hesdorffer D, Moshé SL, Zuberi SM, Medina MT, Bergen D (2015) ICD coding for epilepsy: past, present, and future—a report by the International League Against Epilepsy Task Force on ICD codes in epilepsy. Epilepsia 56(3):348–355. doi:10.1111/epi.12895 CrossRefPubMedGoogle Scholar
  12. 12.
    Hsia Y, Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Sen F, Giaquinto C, Ceci A, Wong IC, TEDDY Network of Excellence (2010) Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia 51(5):789–796. doi:10.1111/j.1528-1167.2009.02331.x CrossRefPubMedGoogle Scholar
  13. 13.
    Giussani G, Franchi C, Messina P, Nobili A, Beghi E, EPIRES Group (2014) Prevalence and incidence of epilepsy in a well-defined population of Northern Italy. Epilepsia 55(10):1526–1533. doi:10.1111/epi.12748 CrossRefPubMedGoogle Scholar
  14. 14.
    Dorks M, Langner I, Timmer A, Garbe E (2013) Treatment of paediatric epilepsy in Germany: antiepileptic drug utilisation in children and adolescents with a focus on new antiepileptic drugs. Epilepsy Res 103(1):45–53. doi:10.1016/j.eplepsyres.2012.06.008 CrossRefPubMedGoogle Scholar
  15. 15.
    Christensen J, Vestergaard M, Pedersen MG, Pedersen CB, Olsen J, Sidenius P (2007) Incidence and prevalence of epilepsy in Denmark. Epilepsy Res 76(1):60–65. doi:10.1016/j.eplepsyres.2007.06.012 CrossRefPubMedGoogle Scholar
  16. 16.
    Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D, Medical Research Council MESS Study Group (2005) Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 365(9476):2007–2013. doi:10.1016/S0140-6736(05)66694-9 CrossRefPubMedGoogle Scholar
  17. 17.
    Marson AG, Al-Kharusi AM, Alwaidh M et al (2007) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369(9566):1016–1026. doi:10.1016/S0140-6736(07)60461-9 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cohen SA, Lawson JA, Graudins LV, Pearson SA, Gazarian M (2012) Changes in anticonvulsant prescribing for Australian children: implications for quality use of medicines. J Paediatr Child Health 48(6):490–495. doi:10.1111/j.1440-1754.2011.02223.x CrossRefPubMedGoogle Scholar
  19. 19.
    Appleton RE, Freeman A, Cross JH (2012) Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline. Arch Dis Child 97(12):1073–1076. doi:10.1136/archdischild-2012-302822 CrossRefPubMedGoogle Scholar
  20. 20.
    Brodie MJ, Kwan P (2012) Current position of phenobarbital in epilepsy and its future. Epilepsia 53(Suppl 8):40–46. doi:10.1111/epi.12027 CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang LL, Zeng LN, Li YP (2011) Side effects of phenobarbital in epilepsy: a systematic review. Epileptic Disord 13(4):349–365. doi:10.1684/epd.2011.0444 PubMedGoogle Scholar
  22. 22.
    Rochat P, Hallas J, Gaist D, Friis ML (2001) Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neurol Scand 104(1):6–11CrossRefPubMedGoogle Scholar
  23. 23.
    Tsiropoulos I, Gichangi A, Andersen M, Bjerrum L, Gaist D, Hallas J (2006) Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand 113(6):405–411. doi:10.1111/j.1600-0404.2006.00639.x CrossRefPubMedGoogle Scholar
  24. 24.
    Egunsola O, Sammons HM, Whitehouse WP (2016) Monotherapy or polytherapy for childhood epilepsies? Arch Dis Child 101(4):356–358. doi:10.1136/archdischild-2015-309466 CrossRefPubMedGoogle Scholar
  25. 25.
    Glauser T, Ben-Menachem E, Bourgeois B et al (2006) ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47(7):1094–1120. doi:10.1111/j.1528-1167.2006.00585.x CrossRefPubMedGoogle Scholar
  26. 26.
    Glauser T, Ben-Menachem E, Bourgeois B et al (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54(3):551–563. doi:10.1111/epi.12074 CrossRefPubMedGoogle Scholar
  27. 27.
    Camfield C, Camfield P, Gordon K, Smith B, Dooley J (1993) Outcome of childhood epilepsy: a population-based study with a simple predictive scoring system for those treated with medication. J Pediatr 122(6):861–868CrossRefPubMedGoogle Scholar
  28. 28.
    Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51(6):1069–1077. doi:10.1111/j.1528-1167.2009.02397.x CrossRefPubMedGoogle Scholar
  29. 29.
    Italiano D, Capuano A, Alibrandi A, Ferrara R, Cannata A, Trifirò G, Sultana J, Ferrajolo C, Tari M, Tari DU, Perrotta M, Pagliaro C, Rafaniello C, Spina E, Arcoraci V (2015) Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005 to 2011. Br J Clin Pharmacol 79(6):1010–1019. doi:10.1111/bcp.12577 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kwong KL, Tsui KW, Wu SP, Yung A, Yau E, Eva F, Ma CK, Cherk S, Liu KT, Cheng WW, Yau MM (2012) Utilization of antiepileptic drugs in Hong Kong children. Pediatr Neurol 46(5):281–286. doi:10.1016/j.pediatrneurol.2012.02.019 CrossRefPubMedGoogle Scholar
  31. 31.
    Tekgül H, Gencpinar P, Çavuşoğlu D, Dündar NO (2016) The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population. Seizure 36:16–21. doi:10.1016/j.seizure.2016.01.017 CrossRefPubMedGoogle Scholar
  32. 32.
    Guerrini R, Zaccara G, la Marca G, Rosati A (2012) Safety and tolerability of antiepileptic drug treatment in children with epilepsy. Drug Saf 35(7):519–533. doi:10.2165/11630700-000000000-00000 CrossRefPubMedGoogle Scholar
  33. 33.
    Bourgeois FT, Olson KL, Poduri A, Mandl KD (2015) Comparison of drug utilization patterns in observational data: antiepileptic drugs in pediatric patients. Paediatr Drugs 17(5):401–410. doi:10.1007/s40272-015-0139-z CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Ramos-Lizana J, Rodriguez-Lucenilla MI, Aguilera-López P, Aguirre-Rodríguez J, Cassinello-García E (2012) A study of drug-resistant childhood epilepsy testing the new ILAE criteria. Seizure 21(4):266–272. doi:10.1016/j.seizure.2012.01.009 CrossRefPubMedGoogle Scholar
  35. 35.
    Giussani G, Canelli V, Bianchi E, Franchi C, Nobili A, Erba G, Beghi E, EPIRES Group (2016) A population-based study of active and drug-resistant epilepsies in northern Italy. Epilepsy Behav 55:30–37. doi:10.1016/j.yebeh.2015.11.021 CrossRefPubMedGoogle Scholar
  36. 36.
    Cramer JA, Wang ZJ, Chang E, Powers A, Copher R, Cherepanov D, Broder MS (2014) Healthcare utilization and costs in children with stable and uncontrolled epilepsy. Epilepsy Behav 32:135–141. doi:10.1016/j.yebeh.2014.01.016 CrossRefPubMedGoogle Scholar
  37. 37.
    Salih MR, Bahari MB, Shafie AA, Hassali MA, Al-lela OQ, Abd AY, Ganesan VM (2012) Medical care costs of newly diagnosed children with structural-metabolic epilepsy: a one year prevalence-based approached. Seizure 21(10):764–769. doi:10.1016/j.seizure.2012.08.005 CrossRefPubMedGoogle Scholar
  38. 38.
    Ryan JL, McGrady ME, Guilfoyle SM, Junger K, Arnett AD, Modi AC (2015) Health care charges for youth with newly diagnosed epilepsy. Neurology 85(6):490–497. doi:10.1212/WNL.0000000000001746 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Clavenna A, Berti A, Gualandi L, Rossi E, De RM, Bonati M (2009) Drug utilisation profile in the Italian paediatric population. Eur J Pediatr 168(2):173–180. doi:10.1007/s00431-008-0725-y CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Laboratory for Mother and Child Health, Department of Public HealthIRCCS—Istituto di Ricerche Farmacologiche “Mario Negri”MilanItaly
  2. 2.Lombardy Region, Region Health MinistryMilanItaly
  3. 3.Epilepsy Center, Health Sciences DepartmentUniversità degli Studi di Milano, San Paolo HospitalMilanItaly

Personalised recommendations